Publications by authors named "Jessica Altman"

Claim this Profile
T
Targeted triplet therapies incorporating FLT3 or IDH inhibitors: ready for prime time?
Himachandana Atluri, Yasmin Abaza, Jessica K Altman

Hematology Am Soc Hematol Educ Program· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of relapsed or refractory acute myeloid leukemia after menin inhibition failure.
Kuo-Kai Chin, Brian J Ball, Yasmin Abaza, Jessica K Altman, Rahul K Thakur

Blood Adv· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Donor-derived acute myeloid leukemia after solid organ transplant: evidence for leukemic stem cell transmission.
Alok Swaroop, Timothy Oh, Kristy Wolniak, Madina Sukhanova, Xinyan Lu, Jessica K Altman

Leuk Lymphoma· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting scavenger receptor class B type 1 with a bioinspired ligand induces apoptosis or ferroptosis in AML.
Adam Y Lin, Jonathan S Rink, Eva Yang, Sara Small, Jessica J Gerber, Jessica Altman

Blood Neoplasia· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Z
Ziftomenib in Relapsed or Refractory -Mutated AML.
Eunice S Wang, Pau Montesinos, James Foran, Harry Erba, Eduardo Rodríguez-Arbolí, Jessica K Altman

J Clin Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimizing lower intensity triplet therapy in acute myeloid leukemia: a practical guide.
Wei-Ying Jen, Curtis A Lachowiez, Jennifer Marvin-Peek, Jessica K Altman, Musa Yilmaz

Blood Cancer J· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing drivers of disparate outcomes and applicability of risk stratification in a cohort of patients with myelofibrosis.
Andrew Palmer, Garth Rauscher, Alexa Schoen, Madelyn Burkart, Ashley Dunton, Jessica K Altman

Blood Cancer J· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Modernizing Eligibility Criteria on Enrollment and Representation in Acute Myeloid Leukemia Clinical Trials.
Andrew Hantel, Yating Wang, Angel Cronin, Irum Khan, Ivy Elizabeth Abraham, Jessica K Altman

Blood· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinicopathologic Characteristics and Prognostic Profile of Chronic Myeloid Neoplasms With Somatic NF1 Mutations in Adult Patients.
Hamza Tariq, Margarita Loxas, Mir B Alikhan, Juehua Gao, Xinyan Lu, Jessica K Altman

Eur J Haematol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Academic Community Partnership in Acute Promyelocytic Leukemia and Early Mortality: The ECOG-ACRIN EA9131 Trial.
Anand P Jillella, Sandra J Lee, Jessica K Altman, Selina M Luger, Martin S Tallman

JAMA Oncol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acute myeloid leukemia management and research in 2025.
Hagop M Kantarjian, Courtney D DiNardo, Tapan M Kadia, Naval G Daver, Jessica K Altman

CA Cancer J Clin· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Z
Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial.
Eunice S Wang, Ghayas C Issa, Harry P Erba, Jessica K Altman, Pau Montesinos

Lancet Oncol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Air pollutant impact on disease characteristics and outcomes in patients with acute myeloid leukemia.
Andrew Palmer, Garth Rauscher, Ivy Abraham, Madelyn Burkart, Ami Dave, Jessica K Altman

Blood Adv· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Randomized Study to Determine the Effect of a Culturally Focused Video Intervention on Improving HPV Vaccine Intentions in a Christian Population in the United States.
David S Redd, Jessica D Altman, Jamie L Jensen, Chantel D Sloan-Aagard, Triston B Crook

J Community Health· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Table Stakes for Equity - Consumer Demographic Data at a State-Based Marketplace.
S Monica Soni, Jessica Altman

N Engl J Med· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CSF3R mutated myeloid neoplasms: Beyond chronic neutrophilic leukemia.
Ahmed Mohamed, Juehua Gao, Yi-Hua Chen, Yasmin Abaza, Jessica Altman

Hum Pathol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical implications of additional chromosomal abnormalities in adult acute myeloid leukemia with inv (16)/t(16;16)/CBFB::MYH11.
Juehua Gao, Lucas Santana-Santos, Lucy Fu, Emily Alvey, Qing Chen, Jessica K Altman

Eur J Haematol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1 study of the irreversible FLT3 inhibitor FF-10101 in relapsed or refractory acute myeloid leukemia.
Mark Levis, Alexander Perl, Gary Schiller, Amir T Fathi, Gail Roboz, Jessica Altman

Blood Adv· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical outcomes of hypomethylating agents plus Venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: Real-world data from eight US academic centers.
Yasmin Abaza, Eric S Winer, Guru Subramanian Guru Murthy, Rory M Shallis, Andrew H Matthews, Jessica K Altman

Am J Hematol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CML and the WHO: Why?
Ellin Berman, Neil P Shah, Michael Deninger, Jessica K Altman, Maria Amaya

J Clin Oncol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
Neil P Shah, Ravi Bhatia, Jessica K Altman, Maria Amaya, Kebede H Begna

J Natl Compr Canc Netw· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PRL2 Phosphatase Promotes Oncogenic KIT Signaling in Leukemia Cells through Modulating CBL Phosphorylation.
Hongxia Chen, Yunpeng Bai, Michihiro Kobayashi, Shiyu Xiao, Sergio Barajas, Jessica K Altman

Mol Cancer Res· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-reported symptom monitoring and adherence to therapy in patients with newly diagnosed chronic myeloid leukemia.
Fabio Efficace, Francesco Cottone, Betina Yanez, Vamsi Kota, Fausto Castagnetti, Jessica K Altman

Cancer· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or acute myeloid leukemia refractory to hypomethylating agents.
Jan Philipp Bewersdorf, Rory M Shallis, Elad Sharon, Silvia Park, Rahul Ramaswamy, Jessica K Altman

Ann Hematol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aspacytarabine for the treatment of patients with AML unfit for intensive chemotherapy: a phase 2 study.
Jessica K Altman, Tsila Zuckerman, Jamie Koprivnikar, James McCloskey, Vamsi Kota

Blood Adv· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis